Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach-A Novel and Potential Antibacterial Formulation
The aim of this study was to design, optimize, and develop metronidazole (Met) loaded nanoparticles (MetNp) by employing quality-based design (QbD) as well as a risk assessment methodology. A fractional factorial design was used by selecting five independent variables viz., chitosan concentration, tripolyphosphate concentration, and acetic acid concentration as material attributes, stirring speed, and stirring time as process parameters, whereby their influence on two dependent variables such as particle size (PS) and %entrapment efficiency (%EE) was studied. MetNp were synthesized by employing an ionic-gelation technique and optimized formula obtained from the QbD design study. PS and %EE studies revealed the formation of MetNp with 558.06 ± 2.52 nm and 59.07 ± 2.15%, respectively. Furthermore, a Met release study in various simulated gastro-intestinal media suggested pH-triggered (pH > 7.0) and sustained release profile of Met from Eudragit S100 enteric-coated MetNp capsule (MetNp cap). Moreover, the stability investigation of formulations confirmed good stability with respect to their PS and residual drug content (RDC) at different temperature conditions. In conclusion, the QbD method was effectively utilized in the development of MetNp and enteric-coated MetNp cap depicting their potential to release Met through MetNp cap only in the colon region and can be utilized for the treatment of amoebiasis in the colon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Pharmaceutics - 12(2020), 10 vom: 25. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sreeharsha, Nagaraja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chitosan |
|---|
| Anmerkungen: |
Date Revised 03.11.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pharmaceutics12100920 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315634812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315634812 | ||
| 003 | DE-627 | ||
| 005 | 20231225155338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics12100920 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315634812 | ||
| 035 | |a (NLM)32992903 | ||
| 035 | |a (PII)E920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sreeharsha, Nagaraja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of Metronidazole Loaded Chitosan Nanoparticles Using QbD Approach-A Novel and Potential Antibacterial Formulation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The aim of this study was to design, optimize, and develop metronidazole (Met) loaded nanoparticles (MetNp) by employing quality-based design (QbD) as well as a risk assessment methodology. A fractional factorial design was used by selecting five independent variables viz., chitosan concentration, tripolyphosphate concentration, and acetic acid concentration as material attributes, stirring speed, and stirring time as process parameters, whereby their influence on two dependent variables such as particle size (PS) and %entrapment efficiency (%EE) was studied. MetNp were synthesized by employing an ionic-gelation technique and optimized formula obtained from the QbD design study. PS and %EE studies revealed the formation of MetNp with 558.06 ± 2.52 nm and 59.07 ± 2.15%, respectively. Furthermore, a Met release study in various simulated gastro-intestinal media suggested pH-triggered (pH > 7.0) and sustained release profile of Met from Eudragit S100 enteric-coated MetNp capsule (MetNp cap). Moreover, the stability investigation of formulations confirmed good stability with respect to their PS and residual drug content (RDC) at different temperature conditions. In conclusion, the QbD method was effectively utilized in the development of MetNp and enteric-coated MetNp cap depicting their potential to release Met through MetNp cap only in the colon region and can be utilized for the treatment of amoebiasis in the colon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Eudragit S100 | |
| 650 | 4 | |a QbD | |
| 650 | 4 | |a chitosan | |
| 650 | 4 | |a colon-specific delivery | |
| 650 | 4 | |a metronidazole | |
| 650 | 4 | |a nanoparticles | |
| 700 | 1 | |a Rajpoot, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Muktika |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyane, Dnyaneshwar |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Anroop B |e verfasserin |4 aut | |
| 700 | 1 | |a Venugopala, Katharigatta N |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Rakesh K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 12(2020), 10 vom: 25. Sept. |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:10 |g day:25 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics12100920 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 10 |b 25 |c 09 | ||